What Teva-Sumatriptan DF Treats: Main Uses and Benefits

Teva-Sumatriptan DF is a specialized medication applied across domains where additional symptomatic support is needed, relevant for easing the symptoms of moderate-to-severe migraine attacks in adults. It is commonly used to help manage symptoms that interfere with daily comfort during these episodic, disruptive manifestations. This fast-acting formulation is applied in settings where short-term symptomatic assistance is important, useful in scenarios where symptoms escalate temporarily.

---

The medication is considered relevant across domains where additional symptomatic support is needed, such as in the management of symptoms linked to migraine with aura and migraine without aura. It is relevant for managing symptoms that interfere with daily comfort, encompassing manifestations like severe, pulsating head pain, along with photophobia, phonophobia, and nausea. This is commonly used when symptoms intensify and supportive relief is appropriate, supporting the patient during difficult episodes by easing distress. The medication contributes to easing the overall symptom load, providing support that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Migraine Symptoms
Primary Symptom Targeted	Severe, throbbing, or pulsating head pain
Associated Symptoms Managed	Photophobia, phonophobia, nausea, and vomiting
Typical Use Context	Acute states of moderate-to-severe pain
Patient Benefit	Supports functional stability and eases symptom burden

Regulatory References

1. NIH MedlinePlus overview

Teva-Sumatriptan DF is for use by adults (18 to 65 years) who have received a clear diagnosis of migraine. Official regulatory labeling establishes strict population eligibility rules, with numerous groups formally excluded from use.

Contraindicated Populations (Must Not Use)

This medicine is contraindicated (absolutely forbidden) for patients with a history or current presence of:

• Cardiovascular and Cerebrovascular Conditions: Ischemic Coronary Artery Disease (CAD), Coronary Artery Vasospasm (Prinzmetal’s angina), history of Stroke or Transient Ischemic Attack (TIA), uncontrolled Severe Hypertension, Peripheral Vascular Disease, or Wolff-Parkinson-White syndrome.
• Specific Migraine Types: Hemiplegic or Basilar Migraine.
• Organ Function: Severe Hepatic Impairment.
• Concurrent Drug Use: Use of a Monoamine Oxidase-A (MAO-A) inhibitor within the preceding two weeks, or use of any other Triptan or Ergotamine-containing medication within the preceding 24 hours.

Age-Related and Conditional Eligibility

Population Group	Regulatory Status
Pediatric Population (Under 18)	Not recommended; safety and efficacy are not established.
Older Adults (Over 65)	Not recommended; clinical experience is limited.
Mild to Moderate Hepatic Impairment	Use is conditional, requiring consideration of a restricted maximum single dose.
Pregnancy / Lactation	Use in pregnancy requires the expected benefit to outweigh possible risk; breastfeeding mothers should avoid nursing for 12 hours after treatment.

The interaction profile for Sumatriptan is defined by mandated prohibitions related to its primary metabolic pathway and documented pharmacodynamic effects. The regulatory documents specify two main classifications of interactions: Contraindicated Combinations and Use-With-Caution Combinations.

Interacting Substance Class	Regulatory Constraint	Key Requirement
MAO-A Inhibitors	Co-administration is formally contraindicated.	Must not be used concurrently or within 2 weeks of stopping MAO-A therapy.
Ergotamine or other 5-HT1 Agonists	Co-administration is formally contraindicated.	Must not be used within 24 hours of Sumatriptan.

The prohibition with MAO-A inhibitors is based on a pharmacokinetic interaction: these agents inhibit the Monoamine Oxidase A enzyme, which significantly reduces Sumatriptan clearance and can increase systemic exposure by approximately 7-fold. The contraindication with Ergotamine-containing medications and other triptans is due to the potential for additive vasoconstrictive effects, raising the risk of prolonged vasospasm.

Furthermore, co-administration with SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin Norepinephrine Reuptake Inhibitors) is associated with the risk of Serotonin Syndrome, which is a documented pharmacodynamic interaction. Use of Sumatriptan is also formally contraindicated in patients with severe hepatic impairment because reduced liver function leads to markedly increased systemic exposure.

Targeted Agonism of Serotonin 5-HT Receptors

Teva-Sumatriptan DF acts as a selective agonist for the 5 -HT1 B and 5 -HT1 D receptors, binding to and activating these specific sites primarily within the trigeminovascular system. This dual targeting initiates a physiological response that modulates two key components of the neurovascular mechanism: cranial blood flow and neural signaling.

---

Regulation of Cranial Vascular Tone

Activation of the 5 -HT1 B receptors on the smooth muscle of extracerebral cranial arteries induces vasoconstriction, which influences the state of vessel dilation. This mechanism results in modulation of intracranial extracerebral vascular dynamics and influences vascular tone.

---

Inhibition of Pro-Inflammatory Neuropeptides

Simultaneously, activation of the 5 -HT1 D receptors on the presynaptic terminals of the trigeminal nerve suppresses the release of potent pro-inflammatory vasoactive mediators, such as Calcitonin Gene-Related Peptide (CGRP). This inhibition results in the attenuation of neurogenic inflammation and influences the activation state of the nerve fibers.

How Teva-Sumatriptan DF is used: Official Administration Guidelines

Teva-Sumatriptan DF is an oral medication with established usage instructions for the acute treatment of episodes. It is not indicated for the prevention (prophylaxis) of these attacks.

Standard Dosing and Administration

Instruction	Detail
Route of Administration	Oral (by mouth) only.
Initial Single Dose	25 mg, 50 mg, or 100 mg. Tablets should be swallowed whole with water.
Maximum Single Dose	100 mg.
Maximum 24-Hour Dose	200 mg.
Dose Interval	At least two hours must pass between doses.

---

Procedural Use Rules

The medicine should be taken at the first sign of a migraine headache. The protocol includes specific rules regarding repeat dosing:

• A second dose may be considered only if the patient experienced some initial response but the episode later returned or partially improved.
• If the first dose provided no response to the attack, a second dose should not be taken for the same episode.
• The safety of treating an average of more than four headaches in a 30-day period has not been established.

Population-Specific Instructions

• Hepatic Impairment: For patients with mild to moderate hepatic impairment, the maximum single dose should not exceed 50 mg.
• Pediatric/Geriatric Use: The use of the oral tablet is not recommended in individuals under 18 years of age or over 65 years of age.

Recent Clinical Evidence Overview

Teva-Sumatriptan DF (sumatriptan succinate) is an acute treatment for migraine attacks in adults, with or without aura. Clinical evidence from randomized, placebo-controlled trials has primarily focused on the effectiveness of the oral tablet formulation and the speed of its effect on migraine pain and associated symptoms.

---

Key Efficacy Findings in Adults

Studies examining oral sumatriptan found that it affected two key outcomes within two hours of administration:

1. Pain-Free Status (Two Hours): In trials involving the 100 mg dose, approximately 3 out of 10 participants achieved a pain-free state within two hours, compared to approximately 1 out of 10 participants taking placebo.
2. Pain Relief (Two Hours): Pain relief (defined as reduction of moderate or severe pain to mild or none) was reported by approximately 6 out of 10 participants taking the 100 mg dose, compared to approximately 3 out of 10 participants taking placebo.

It has been observed that treatment of a migraine attack while the pain is still mild may be associated with higher rates of a pain-free response compared to treating pain that has already reached moderate or severe intensity. The medication was also found to influence associated symptoms, such as nausea and sensitivity to light and sound (photophobia and phonophobia), within the same two-hour timeframe.

---

Other Research Considerations

• Dose Comparison: Clinical data suggest the 100 mg dose has a slightly higher rate of achieving pain-free status compared to the 50 mg dose, though the 50 mg dose may be associated with fewer adverse events overall.
• Pediatric Use: The safety and effectiveness of oral sumatriptan have not been definitively established for the acute treatment of migraine in children and adolescents, and its use in this population is generally not recommended without physician guidance.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE) Guideline: Headaches in over 12s: diagnosis and management
2. Migraine Treatment: Acute Medication

Common questions about Teva-Sumatriptan DF (FAQ)

Q: What is Teva-Sumatriptan DF used for?

Teva-Sumatriptan DF is used for the acute treatment of migraine attacks with or without aura. It is not intended to prevent migraines or to treat a headache that is different from your usual migraine.

Q: How does Teva-Sumatriptan DF work?

Teva-Sumatriptan DF belongs to a class of medicines called selective serotonin receptor agonists (also known as triptans). It is thought to work by constricting blood vessels that are dilated around the brain and by stopping the release of substances that cause migraine symptoms, such as pain and inflammation.

Q: How should I take Teva-Sumatriptan DF?

Take Teva-Sumatriptan DF as soon as the migraine headache starts, but it can be taken at any time during the attack. The tablet should be swallowed whole with water. Do not take it to prevent a migraine. It is important to follow the dosage instructions provided by your healthcare professional.

Q: Can I take a second dose if my migraine returns?

If the first dose eases your migraine but the pain comes back later, you may take a second dose, provided it is at least two hours after the first dose. Do not take more than two doses within 24 hours.

Q: What should I do if the first dose doesn't work?

If you take one dose of Teva-Sumatriptan DF and your migraine does not improve, do not take a second dose for the same attack. For this migraine attack, you may use your usual non-triptan pain reliever (like acetaminophen or ibuprofen). If your headache doesn't improve, speak with your doctor.

Q: What are the common side effects of Teva-Sumatriptan DF?

Common side effects can include temporary symptoms such as:

• Tingling or numbness
• Dizziness or feeling weak
• Drowsiness
• Feeling of warmth or cold
• Tightness, pain, pressure, or heaviness in the chest, throat, neck, or jaw

These side effects are usually mild and short-lived. If they are severe or do not go away, contact your healthcare provider.

Q: Can I take Teva-Sumatriptan DF if I am pregnant or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits of taking Teva-Sumatriptan DF with your doctor. Your doctor will weigh the potential risk to the baby against the benefit of treatment for you.

How to Store and Dispose of Teva-Sumatriptan DF?

Teva-Sumatriptan DF tablets require storage at controlled room temperature, specifically between 15 C and 30 C. The medication must be kept in its original, tightly closed container and stored in a cool, dry place to ensure product stability. It is mandatory to protect the tablets from light, moisture, and excessive heat, and the product must never be frozen.

Protective Handling and Disposal

All tablets must be kept out of the sight and reach of children to prevent accidental ingestion. For disposal, any unused or expired tablets must not be discarded in household trash or wastewater. Official regulations mandate that the product be returned to a pharmacy or disposed of in accordance with local pharmaceutical waste requirements.